Repatha ® (evolocumab) is a human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9). Repatha binds to PCSK9 and inhibits circulating PCSK9 from binding to the low-density lipoprotein (LDL) receptor (LDLR), preventing PCSK9-mediated LDLR degradation and permitting LDLR to recycle back to the liver cell surface.

Mar 1, 2023 · Repatha binds to PCSK9 and inhibits circulating PCSK9 from binding to the low-density lipoprotein (LDL) receptor (LDLR), preventing PCSK9-mediated LDLR degradation and permitting LDLR to recycle back to the liver cell surface.

2 days ago · The long-running legal dispute between Amgen and Sanofi/Regeneron on two key patents covering the use of PCSK9 inhibitors to lower cholesterol has come to an end, with Sanofi emerging as the...

May 18, 2023 · The Washington-based U.S. Court of Appeals for the Federal Circuit, which hears all patent appeals nationwide, invalidated Amgen's patents that covered PCSK9-blocking drugs as a group.

Amgen held two patents for antibodies that bind to specific amino acids on PCSK9, a protein involved in regulating LDL cholesterol. These antibodies were claimed to block PCSK9 from impairing the body's mechanism for removing LDL cholesterol from the bloodstream.

May 18, 2023 · After numerous twists and turns, a highly divisive patent infringement case between Amgen and partners Sanofi and Regeneron has come to an end at the U.S. Supreme Court. The nine justices voted...

Feb 12, 2021 · Amgen's years-long PCSK9 patent crusade has swung once again in Sanofi and Regeneron’s favor. Upholding a lower court’s ruling, the U.S. Federal Circuit Court said it found (PDF) Amgen’s...

Repatha binds to PCSK9 and inhibits circulating PCSK9 from binding to the low-density lipoprotein (LDL) receptor (LDLR), preventing PCSK9-mediated LDLR degradation and permitting LDLR to recycle back to the liver cell surface.

Oct 25, 2019 · Amgen has always been locked in a battle for market share with Regeneron and Sanofi’s PCSK9 drug Praluent—a war that escalated earlier this year when the two companies slashed Praluent’s price to...

May 18, 2023 · In a unanimous decision authored by Justice Neil Gorsuch, the court said two Amgen patents on its PCSK9 inhibitor Repatha fell short of a legal standard known as enablement, which requires the claimed invention be described well enough to allow a skilled person in the field to use it.